Connective tissue disease-associated interstitial lung diseases (CTD-ILD) - Report from OMERACT CTD-ILD working group

Dinesh Khanna, Shikha Mittoo, Rohit Aggarwal, Susanna M. Proudman, Nicola Dalbeth, Eric Lawrence Matteson, Kevin Brown, Kevin Flaherty, Athol U. Wells, James R. Seibold, Vibeke Strand

Research output: Contribution to journalArticle

47 Citations (Scopus)

Abstract

Objective. Interstitial lung disease (ILD) is common in connective tissue disease (CTD) and is the leading cause of mortality. Investigators have used certain outcome measures in randomized controlled trials (RCT) in CTD-ILD, but the lack of a systematically developed, CTD-specific index that captures all measures relevant and meaningful to patients with CTD-ILD has left a large and conspicuous gap in CTD-ILD research. Methods. The CTD-ILD working group, under the aegis of the Outcome Measures in Rheumatology (OMERACT) initiative, has completed a consensus group exercise to reach harmony on core domains and items for inclusion in RCT in CTD-ILD. During the OMERACT 12 meeting, consensus was sought on domains and core items for inclusion in RCT. In addition, consensus was pursued on a definition of response in RCT. Consensus was defined as > 75% agreement among the participants. Results. OMERACT 12 participants endorsed the domains with minimal modifications. Clinically meaningful progression for CTD-ILD was proposed as > 10% relative decline in forced vital capacity (FVC) or > 5% to <10% relative decline in FVC and > 15% relative decline in DLCO. Conclusion. There is consensus on domains for inclusion in RCT in CTD-ILD and on a definition of clinically meaningful progression. Data-driven approaches to validate these results in different cohorts and RCT are needed.

Original languageEnglish (US)
Pages (from-to)2168-2171
Number of pages4
JournalJournal of Rheumatology
Volume42
Issue number11
DOIs
StatePublished - Nov 1 2015

Fingerprint

Connective Tissue Diseases
Interstitial Lung Diseases
Randomized Controlled Trials
Outcome Assessment (Health Care)
Vital Capacity
Rheumatology
Research Personnel
Exercise
Mortality

Keywords

  • Interstitial lung disease
  • Lung diseases
  • Outcome assessment omeract

ASJC Scopus subject areas

  • Rheumatology
  • Immunology
  • Immunology and Allergy

Cite this

Connective tissue disease-associated interstitial lung diseases (CTD-ILD) - Report from OMERACT CTD-ILD working group. / Khanna, Dinesh; Mittoo, Shikha; Aggarwal, Rohit; Proudman, Susanna M.; Dalbeth, Nicola; Matteson, Eric Lawrence; Brown, Kevin; Flaherty, Kevin; Wells, Athol U.; Seibold, James R.; Strand, Vibeke.

In: Journal of Rheumatology, Vol. 42, No. 11, 01.11.2015, p. 2168-2171.

Research output: Contribution to journalArticle

Khanna, D, Mittoo, S, Aggarwal, R, Proudman, SM, Dalbeth, N, Matteson, EL, Brown, K, Flaherty, K, Wells, AU, Seibold, JR & Strand, V 2015, 'Connective tissue disease-associated interstitial lung diseases (CTD-ILD) - Report from OMERACT CTD-ILD working group', Journal of Rheumatology, vol. 42, no. 11, pp. 2168-2171. https://doi.org/10.3899/jrheum.141182
Khanna, Dinesh ; Mittoo, Shikha ; Aggarwal, Rohit ; Proudman, Susanna M. ; Dalbeth, Nicola ; Matteson, Eric Lawrence ; Brown, Kevin ; Flaherty, Kevin ; Wells, Athol U. ; Seibold, James R. ; Strand, Vibeke. / Connective tissue disease-associated interstitial lung diseases (CTD-ILD) - Report from OMERACT CTD-ILD working group. In: Journal of Rheumatology. 2015 ; Vol. 42, No. 11. pp. 2168-2171.
@article{140dfcd0769c43c9952a7b08c26f5f16,
title = "Connective tissue disease-associated interstitial lung diseases (CTD-ILD) - Report from OMERACT CTD-ILD working group",
abstract = "Objective. Interstitial lung disease (ILD) is common in connective tissue disease (CTD) and is the leading cause of mortality. Investigators have used certain outcome measures in randomized controlled trials (RCT) in CTD-ILD, but the lack of a systematically developed, CTD-specific index that captures all measures relevant and meaningful to patients with CTD-ILD has left a large and conspicuous gap in CTD-ILD research. Methods. The CTD-ILD working group, under the aegis of the Outcome Measures in Rheumatology (OMERACT) initiative, has completed a consensus group exercise to reach harmony on core domains and items for inclusion in RCT in CTD-ILD. During the OMERACT 12 meeting, consensus was sought on domains and core items for inclusion in RCT. In addition, consensus was pursued on a definition of response in RCT. Consensus was defined as > 75{\%} agreement among the participants. Results. OMERACT 12 participants endorsed the domains with minimal modifications. Clinically meaningful progression for CTD-ILD was proposed as > 10{\%} relative decline in forced vital capacity (FVC) or > 5{\%} to <10{\%} relative decline in FVC and > 15{\%} relative decline in DLCO. Conclusion. There is consensus on domains for inclusion in RCT in CTD-ILD and on a definition of clinically meaningful progression. Data-driven approaches to validate these results in different cohorts and RCT are needed.",
keywords = "Interstitial lung disease, Lung diseases, Outcome assessment omeract",
author = "Dinesh Khanna and Shikha Mittoo and Rohit Aggarwal and Proudman, {Susanna M.} and Nicola Dalbeth and Matteson, {Eric Lawrence} and Kevin Brown and Kevin Flaherty and Wells, {Athol U.} and Seibold, {James R.} and Vibeke Strand",
year = "2015",
month = "11",
day = "1",
doi = "10.3899/jrheum.141182",
language = "English (US)",
volume = "42",
pages = "2168--2171",
journal = "Journal of Rheumatology",
issn = "0315-162X",
publisher = "Journal of Rheumatology",
number = "11",

}

TY - JOUR

T1 - Connective tissue disease-associated interstitial lung diseases (CTD-ILD) - Report from OMERACT CTD-ILD working group

AU - Khanna, Dinesh

AU - Mittoo, Shikha

AU - Aggarwal, Rohit

AU - Proudman, Susanna M.

AU - Dalbeth, Nicola

AU - Matteson, Eric Lawrence

AU - Brown, Kevin

AU - Flaherty, Kevin

AU - Wells, Athol U.

AU - Seibold, James R.

AU - Strand, Vibeke

PY - 2015/11/1

Y1 - 2015/11/1

N2 - Objective. Interstitial lung disease (ILD) is common in connective tissue disease (CTD) and is the leading cause of mortality. Investigators have used certain outcome measures in randomized controlled trials (RCT) in CTD-ILD, but the lack of a systematically developed, CTD-specific index that captures all measures relevant and meaningful to patients with CTD-ILD has left a large and conspicuous gap in CTD-ILD research. Methods. The CTD-ILD working group, under the aegis of the Outcome Measures in Rheumatology (OMERACT) initiative, has completed a consensus group exercise to reach harmony on core domains and items for inclusion in RCT in CTD-ILD. During the OMERACT 12 meeting, consensus was sought on domains and core items for inclusion in RCT. In addition, consensus was pursued on a definition of response in RCT. Consensus was defined as > 75% agreement among the participants. Results. OMERACT 12 participants endorsed the domains with minimal modifications. Clinically meaningful progression for CTD-ILD was proposed as > 10% relative decline in forced vital capacity (FVC) or > 5% to <10% relative decline in FVC and > 15% relative decline in DLCO. Conclusion. There is consensus on domains for inclusion in RCT in CTD-ILD and on a definition of clinically meaningful progression. Data-driven approaches to validate these results in different cohorts and RCT are needed.

AB - Objective. Interstitial lung disease (ILD) is common in connective tissue disease (CTD) and is the leading cause of mortality. Investigators have used certain outcome measures in randomized controlled trials (RCT) in CTD-ILD, but the lack of a systematically developed, CTD-specific index that captures all measures relevant and meaningful to patients with CTD-ILD has left a large and conspicuous gap in CTD-ILD research. Methods. The CTD-ILD working group, under the aegis of the Outcome Measures in Rheumatology (OMERACT) initiative, has completed a consensus group exercise to reach harmony on core domains and items for inclusion in RCT in CTD-ILD. During the OMERACT 12 meeting, consensus was sought on domains and core items for inclusion in RCT. In addition, consensus was pursued on a definition of response in RCT. Consensus was defined as > 75% agreement among the participants. Results. OMERACT 12 participants endorsed the domains with minimal modifications. Clinically meaningful progression for CTD-ILD was proposed as > 10% relative decline in forced vital capacity (FVC) or > 5% to <10% relative decline in FVC and > 15% relative decline in DLCO. Conclusion. There is consensus on domains for inclusion in RCT in CTD-ILD and on a definition of clinically meaningful progression. Data-driven approaches to validate these results in different cohorts and RCT are needed.

KW - Interstitial lung disease

KW - Lung diseases

KW - Outcome assessment omeract

UR - http://www.scopus.com/inward/record.url?scp=84946568792&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84946568792&partnerID=8YFLogxK

U2 - 10.3899/jrheum.141182

DO - 10.3899/jrheum.141182

M3 - Article

C2 - 25729034

AN - SCOPUS:84946568792

VL - 42

SP - 2168

EP - 2171

JO - Journal of Rheumatology

JF - Journal of Rheumatology

SN - 0315-162X

IS - 11

ER -